Lymphosarcoma is a common tumour in the dog, an incidence of 24 per 100 000 was given for an area of California. This was greater than the incidence of malignant lymphoid tumours plus leukxemia cases in man, but not as high as the incidence in the cat (Dom et al. 1967 ). Spontaneous cases have not been reported as occurring before the age of 4 months, most occurring between 5 and 11 years old. The main pathological forms are the alimentary, multicentric and thymic varieties. Cases of lymphatic leukxemia are less common and myeloid, plasma-cell and mastcell leukemia are uncommon.
In the alimentary form the small intestine and mesenteric nodes and immediate portal drainage area are mainly affected, whereas in the multicentric form superficial lymph nodes, liver, spleen and kidneys are frequently affected. Lymph nodes are usually very enlarged and show complete loss of architecture often with central necrosis. Histologically some tumours have a nodular pattern but usually there is a uniform field of lymphocytic or lymphoblastic cells. Three distinct groups of histological cell types have been described: lymphocytic well-differentiated, lymphocytic poorly-differentiated and histiocytic. There appears to be no evidence however, for a true macrophage or histiocytic origin (Holmberg et al. 1976 ).
Anxemia is common and is believed to be due to depressed erythropoiesis and increased hiemolysis. There is often neutrophilia but leukaemia or a 'spill-over' only occurs in about 10 % of cases. The uncommon cases of lymphatic leukxemia which occur often present with severe wasting and hepatosplenomegaly. Other clinical signs may be evident especially when meningeal infiltration has occurred but peripheral lymph nodes are not usually greatly enlarged. White blood cell counts can total 500 000 per mm3 with 99 % lymphocytes or lymphoblasts.
During the past few years Owen, Onions, Weiden and other workers have made contributions to the transplantation, immunology, metiology and therapy of canine lymphosarcoma.
Methods

Immunology
The following examinations have been carried out: determination of B-or T-cell origin including cell surfaces visualized with the scanning electron microscope, the presence of surface IgG, mitogenic responsiveness and rosette formation (Holmberg et al. 1976 , Onions 1976 ); determination of IgG levels and the antibody response to sheep red blood cells or to dinitrophenylated serum albumin (Weiden et al. 1974 , Owen et al. 1975 ); skin-graft survival using full thickness allogeneic skin grafts (Owen et al. 1975 ); determination of antibodies to a canine lymphosarcoma-associated antigen using an antigen preparation following homogenization and centrifugation of fresh lymphosarcoma material or material stored at -70°C. Tests were made in immunodiffusion plates (Winters & Snow 1974 , Onions 1976 Moldovanu et al. (1966) have transplanted lymphosarcoma cells into new-born puppies given wholebody X-irradiation. Owen & Neilsen (1968) used a method of transplantation into fetuses. Following laparotomy in an anesthetized pregnant bitch of 6 or 7 weeks gestation, 107-10' fresh canine lymphosarcoma cells were injected intraperitoneally into fetuses, passing the injection needle through the uterine wall. A similar method of transplantation was used, using a mixture of cells from lymph node, spleen, bone marrow and peripheral blood white blood cells collected from a dog with advanced lymphocytic leukemia (Owen 1971) . Nude mice have also been injected with canine lymphosarcoma cells (Onions 1976 ).
Viral Studies
These have included: EM preparations; detection of (poly rc. oligo dg. templated) reverse transcriptase (Onions 1976) ; sucrose gradient analysis of 3H-uridine labelled cells to detect RNA-containing particles of oncorna viral density (Robinson et al. 1965 ).
Therapy
Chemotherapy: A large number of chemotherapeutic agents have been tried on canine lymphosarcoma. One method currently being used is shown in Table 1 .
Immunotherapy: Dogs with spontaneous lymphosarcoma were brought into remission using the quadruple therapy described (Table 1) . At this stage animals were allocated at random into three groups: continuous maintenance chemotherapy (13 dogs); nonspecific immunotherapy using intravenous injections of percutaneous BCG vaccine (Glaxo) containing 50-250 x 106 viable organisms made up to 5 ml in saline (13 dogs); immunotherapy using intravenous injections of BCG vaccine combined with 0l pooled living allogeneic lymphosarcoma cells from untreated cases of canine lymphosarcoma (13 dogs). All dogs given BCG alone or BCG mixed with cells received an intramuscular injection of an antihistaminic drug, mepyramine maleate (Anthisan, May & Baker), 30 minutes before, in order to prevent the development of anaphylactic shock. Immunotherapy was given 3 days after the end of chemotherapy and repeated injections were given at 6-8, 12 and 20 weeks after the start of chemotherapy (Owen et al. 1 977a).
Results
Immunology
Eleven of 16 lymphosarcomas examined by Holmberg et al. (1976) were of B-cell origin. The results indicated that the cells from histiocytic lymphosarcomas were lymphocytes rather than histiocytes or macrophages. Onions (1976) found 18 of 37 lymphosarcomas to be of B-cell origin and 4 of T-cell origin, the latter included two thymic lymphosarcoma cases. In Onions' studies there was also evidence for a mixed-cell group and 2 cases were tentatively classified into a null cell group. Weiden et al. (1974) have demonstrated both lower IgG levels and an impaired antibody response to sheep red blood cells in lymphosarcomabearing dogs. Compared to normal dogs or to dogs bearing other tumours, Owen et al. (1975) found that the secondary immune response to dinitrophenylated human serum albumen is depressed in cases of canine lymphosarcoma. They found no prolongation of survival of allogeneic skin grafts in dogs with lymphosarcoma compared with control dogs. The graft rejection was essentially similar histologically in both lymphosarcoma and normal dogs. In new-born dogs previously injected with normal donor spleen cells in utero there was in some cases a considerable increase in survival of skin grafts from the same donor using the same technique. These results are in contrast to those of Weiden et al. (1974) who found no prolongation of survival of allogeneic skin grafts in dogs with lymphosarcoma.
In spite of the impairment of the immune system, dogs with lymphosarcoma can produce antibody to tumour-associated antigen (Winters & Snow 1974) . Their studies and those of Onions (1976) indicate that the antigen is either located on the cell membrane or in the cytoplasm of the target cells. That this antigen may be present on normal or hyperplastic lymphoid tissue has not, however, been finally excluded.
Transplantation
When cells from a solid lymphosarcoma were injected into unrelated fetuses solid lymphosarcoma became clinically apparent in the puppies within a month of birth. This tumour was again successfully transplanted by intrafetal injection. When cells from a case of true lymphatic leukwemia were injected into fetuses nearly all puppies developed leukamia with peripheral white blood cell counts up to 280 000 per mm3 within about 10 days of birth. This leukmemia was successfully serially transplanted on 3 occasions but cell-free transmission was not successful. In contrast to the successful transplantation of canine osteosarcoma, mammary carcinoma and melanoma in nude mice (Oughton & Owen 1974) , numerous attempts to transplant canine lymphosarcoma have been unsuccessful. Using a canine mast-cell leukemia established in tissue culture, intraperitoneal injections of these cells into nude mice resulted in an ascites tumour. Subcutaneous injections produced a solid tumour with similar histological appearance to that seen in the donor dog (Onions 1976 ).
Viral Studies
During EM studies on lymphosarcoma Chapman et al. (1967) observed budding particles 80-100 nm in diameter with a nucleoid of 50 nm, both in biopsy material and cell cultures of 2 leukvmic dogs. In 4 of 12 dogs described by Rudolph (1971) type-A particles were described. Particles with some of the characteristics of oncornaviruses were found in 6 out of 14 lymphosarcoma biopsies examined and also in the biopsy material from a disseminated mastocytoma. However, no budding forms were seen. In 2 of 11 biopsy specimens of lymphosarcoma, reverse transcriptase (poly rc. oligo dg. templated) was detected (Onions 1976) . In one of these dogs a uridine-containing particle 1.15 g/ml was also detected.
Therapy
The mean survival of untreated dogs is about 2 months (Jarrett et al. 1966) . Administration of corticosteroids often leads to an improvement in the general well-being of the dog with increased appetite and interest, but there is no evidence of prolongation of life. Using the quadruple therapy described, there is complete clinical regression in about 75 % of cases with a mean survival time of approximately 6 months. Toxic effects of the drugs at the doses given have been rare.
The median length of remission in dogs receiving either of the forms of immunotherapy was 6 weeks, whereas the median remission time following continued chemotherapy was 15 weeks. The dogs treated with BCG did not show the wide-spread granulomatous lesions which occur in normal dogs following similar injections. Toxic effects included pyrexia, anorexia and conjunctivitis.
Discussion
While Hodgkins' disease in man accounts for about 400% of lymphomas, it is doubtful if an exactly similar pathological condition occurs in the dog. Cells resembling Sternberg-Reed cells have, however, occasionally been described (Squire 1965 ).
It appears from initial results that many lymphosarcomas in the dog are of B-cell origin. This is similar to the position in non-Hodgkins' lymphomas and to chronic lymphatic leukvmia in man. Avian lymphoid leukosis is also of B-cell origin. Mixed cell lymphomas which Onions has described in the dog have also occured in man.
The technique of intrafetal injection at a stage when the fetus is relatively incompetent immunologically may eventually prove useful in cell-free transmission studies. Transplantation of canine lymphosarcomas into the nude mouse may be possible following whole-body irradiation. Irvin et al. (1977) have shown that it is possible to transplant bovine lymphosarcoma into irradiated nude mice but not into nude mice not so treated.
Initial results on reverse transcriptase activity in canine lymphosarcoma are encouraging enough to pursue a viral etiology for this condition. Experiments on derepression of covert virus using bromo-or iodo-deoxyuridine treatment with subsequent hormone treatment are in progress, as are experiments on sucrose gradient analysis and hybridization techniques. The results of Lombard et al. (1963) and Post et al. (1970) who transmitted mast-cell leukemia to puppies using cell-free filtrates do not appear to have been fully exploited.
Canine lymphosarcoma of the multicentric type is a good model on which to try potentially useful new chemotherapeutic drugs. At the present time the quadruple therapy described is probably the best available therapy for clinical use in veterinary practice. It produces short-term palliation without toxicity. The main disadvantage is the high cost of vincristine and cytosine especially if a large dog is to be treated.
Following amputation of the affected limb and intravenous injections of BCG in 20 dogs with osteosarcoma, 11 lived 6 months or more and 7 lived over a year, which is much better than historical controls (Owen et al. 1977b ). However, when this route of administration was used in dogs in remission from lymphosarcoma there was no demonstrable therapeutic effect whether BCG was administered alone or mixed with allogeneic lymphosarcoma cells.
